THERABRON

Therabron Therapeutics, we are working to change how respiratory diseases are managed. We are aiming to not only provide symptomatic relief, but also to improve long-term health outcomes and reduce healthcare costs. A privately held, clinical-stage, biopharmaceutical corporation, Therabron is developing a new class of drugs from the secretoglobin family of proteins. Our lead product, recombinant human CC10 protein (rhCC10), is a potent anti-inflammatory agent for patients with respiratory diseases.